APRE - Aprea Therapeutics gains 9% on FDA removal of clinical hold on eprenetapopt

Aprea Therapeutics (NASDAQ:APRE) announces that the FDA has removed the full clinical hold on the Company’s trial evaluating the combination of eprenetapopt with acalabrutinib or with venetoclax and rituximab in lymphoid malignancies. Shares up 9.2% premarket at $4.50. “We are pleased to have addressed the FDA’s concerns and receive clearance to proceed with future clinical study of eprenetapopt in non-Hodgkin’s lymphomas,” said Eyal Attar, M.D., Chief Medical Officer of Aprea Therapeutics.

For further details see:

Aprea Therapeutics gains 9% on FDA removal of clinical hold on eprenetapopt